Hepatitis Medicines in India: Imported Options for Hepatitis C and Fatty Liver Hepatitis
The main kinds of hepatitis, and which ones this page covers
The word hepatitis only tells you the liver is inflamed. The cause decides how it spreads, whether it lasts, and which medicine helps. Short-lived infections such as hepatitis A and E usually settle with rest and care. The long-lasting kinds are the ones that slowly scar the liver over many years, and they are where medicines matter.
| Kind | Cause and spread | Course | Medicines on this page |
|---|---|---|---|
| Hepatitis A and E | Virus taken in through unsafe water or food | Usually clears on its own in weeks | None; supportive care |
| Hepatitis B | Virus passed by blood, from mother to baby at birth, or by sex | Can stay for life; controlled with daily tablets | None; generic tablets such as tenofovir are available in India |
| Hepatitis C | Virus passed mainly by blood, for example reused needles or old unscreened transfusions | Usually long-lasting, but a 12-week tablet course can clear it | Retreatment tablet and newer NS5A + NS5B pairs |
| Fatty liver hepatitis (MASH) | Fat inside liver cells, linked with weight, diabetes and blood fats; formerly called NASH | Silent for years; can lead to scarring and cirrhosis | A liver-targeted thyroid-receptor tablet |
| Other causes | Alcohol, some medicines, autoimmune attack | Depends on the cause | Not covered here |
Hepatitis B is shown for completeness. Generic tenofovir is supplied in India at one of the lowest prices WHO recorded [1], and the national programme covers hepatitis B drugs free of charge [4], so no imported hepatitis B medicine is listed on this page.
What Indian data show about hepatitis C and fatty liver
- A free national programme exists. The National Viral Hepatitis Control Program started on 28 July 2018, World Hepatitis Day. Its goal is to eliminate hepatitis C from the country by 2030, and it provides for free tests and drugs for hepatitis B and C, rolled out in phases [4].
- Genotype 3 is the common one. In Punjab's programme, 71.3% of the 50,865 people treated between April 2019 and December 2023 had genotype 3. The overall cure rate was 89.5%. Older age, cirrhosis and missed doses were the factors that predicted a failed course [2].
- A small group is not cured the first time. In a Kolkata study, 89.6% of the patients treated with sofosbuvir plus daclatasvir or ledipasvir were cured. Of the 13 who were not, 92.31% cleared the virus on a second, six-month regimen [5]. Genotype 3b responded less well than 1a and 1b.
- Finishing the course is the hard part. At a government medical college in Patiala, 21.0% of 385 patients dropped out before their cure test, and only 49% of the 304 who completed took at least nine in ten of their tablets. Those who did were more likely to be cured [6].
- Fatty liver is very common. An AIIMS and SGPGI review of 50 Indian studies put fatty liver at 38.6% of adults: 28.1% in average-risk groups and 52.8% in high-risk groups such as people with diabetes or obesity [3]. Only some of these people go on to inflammation and scarring (MASH), which is the stage a medicine is approved for.
When an imported hepatitis medicine makes sense
Most people with hepatitis C in India should start with the national programme: a sofosbuvir-based course with an NS5A tablet (daclatasvir, ledipasvir or velpatasvir) [2], which is free [4]. An imported medicine is usually discussed only in three situations:
- The first course did not work. If the virus is still found 12 weeks after a course that included an NS5A tablet, Vosevi is approved in the US for a second attempt in adults without cirrhosis or with mild, compensated cirrhosis.
- Your doctor prefers a newer pair. Alfosbuvir (with daclatasvir) and the netanasvir + encofosbuvir pair are newer Chinese 12-week courses for genotypes 1, 2, 3 and 6, approved for people never treated before or treated earlier with interferon. They are not approved for retreatment after tablet failure.
- Fatty liver has reached stage F2 or F3 scarring. Rezdiffra is approved in the US, together with diet and exercise, for adults with MASH and moderate to advanced fibrosis who do not yet have cirrhosis.
Imported hepatitis medicines by type
All 5 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.





Compare all 5 hepatitis medicines
| Medicine | Generic name | Hepatitis type | Form | Approved by |
|---|---|---|---|---|
| Vosevi | sofosbuvir + velpatasvir + voxilaprevir | Hepatitis C, Retreatment | Tablet | US FDA |
| Alfosbuvir | alfosbuvir | Hepatitis C | Tablet | China NMPA |
| Netanasvir | netanasvir phosphate | Hepatitis C | Capsule | China NMPA |
| Encofosbuvir | encofosbuvir | Hepatitis C | Tablet | China NMPA |
| Rezdiffra | resmetirom | Fatty liver (MASH) | Tablet | US FDA (accelerated approval) |
Reports your liver specialist will want to see
These medicines are matched to the stage of the illness and to what was tried before, so the paperwork matters as much as the prescription.
| Report | What it shows | Medicines it decides |
|---|---|---|
| HCV RNA (viral load) | Whether the virus is active now; a positive result 12 weeks after a course means it was not cleared | All hepatitis C medicines here |
| HCV genotype | The strain of the virus; the Chinese pairs are approved for genotypes 1, 2, 3 and 6 | Alfosbuvir, Netanasvir + Encofosbuvir |
| List of earlier hepatitis C medicines | Whether an NS5A tablet or sofosbuvir was already used, and whether interferon was given | Vosevi (needs earlier treatment), Chinese pairs (not after tablet failure) |
| FibroScan or liver biopsy | How much scarring there is (F0 to F4) | Rezdiffra (F2–F3 only), and whether cirrhosis is present for hepatitis C |
| Child-Pugh score | Whether cirrhosis is compensated (class A) or decompensated | Vosevi is for class A only; Rezdiffra is avoided in decompensated cirrhosis |
Permit, delivery and help with cost
Every pack is brought in for one named person. The patient is the applicant to CDSCO on Form 12A, and our pharmacist fills it in for them; CDSCO answers by granting a Form 12B permit. The documents needed are listed in our Form 12A and 12B guide. All five medicines here are tablets or capsules, and we can send them to the pharmacy of the hospital where the patient is treated through our hospital delivery service.
A hepatitis C course has a fixed length, while Rezdiffra is a once-a-day tablet whose continued use your doctor reviews over time. Help with cost may come from a maker's scheme, a government option or a charity; our guide to patient support programs gathers them in one place.
How to get these hepatitis medicines in India
Prescription
Your doctor prescribes the medicine.
Share documents
Send the prescription and latest reports through Online Order.
Import paperwork
Our team checks the source and the import permissions.
Delivery
Delivered with the right storage, including cold chain.
Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.
Has your doctor prescribed one of these medicines?
Share the prescription and we will guide you on availability and next steps.
Read more about hepatitis
References
- World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Tables 2.6–2.8. https://iris.who.int/handle/10665/376461
- Premkumar M et al. Impact of resistance associated substitutions and predictors of treatment failure following direct-acting antiviral therapy in a viral hepatitis C elimination cohort. J Clin Exp Hepatol. 2025;15(6):102601. https://pubmed.ncbi.nlm.nih.gov/40611935/
- Shalimar et al. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J Clin Exp Hepatol. 2022;12(3):818-829. https://pubmed.ncbi.nlm.nih.gov/35677499/
- Ministry of Health and Family Welfare. National Viral Hepatitis Control Program – About Us. https://nvhcp.mohfw.gov.in/about_us
- Dutta S et al. Direct-acting antiviral treatment outcomes in chronic hepatitis C with various HCV genotypes: a real-world cohort in West Bengal, India. BMC Infect Dis. 2025;25(1):1180. https://pubmed.ncbi.nlm.nih.gov/41023889/
- Rai SK et al. Determinants of treatment adherence in hepatitis C patients in a public sector setting in India. Am J Trop Med Hyg. 2026;115(5):1071-1076. https://pubmed.ncbi.nlm.nih.gov/42660104/
- US FDA prescribing information for Vosevi and Rezdiffra (DailyMed). https://dailymed.nlm.nih.gov/dailymed/
This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.